Single-injection Ultrasound-guided Erector Spinae Plane Block for Postoperative Analgesia in Patients Undergoing Open Radical Prostatectomy: A Prospective Randomized Sham-controlled Trial
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- BURHAN DOST
- Enrollment
- 52
- Locations
- 1
- Primary Endpoint
- Narcotic consumption in the first 24 hours after surgery
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
In the proposed study, a bilateral erector spinae plane (ESP) block [10 ml 1%lidocaine + 10 ml 0.5 % bupivacaine vs normal saline (NS)] will be performed preoperatively to patients undergoing open radical prostatectomy. Analgesic efficacy will be assessed on the numeric rating scale (NRS) along with intra- and 24 h post-operative narcotic consumption.
Detailed Description
It has been reported that the ESP block produces effective postoperative analgesia for abdominal surgeries by relieving both somatic and visceral pain. In the present study, the investigators presume that an ESP block will decrease narcotic consumption and NRS values both intraoperatively and during the first 24 postoperative hours. Patients will be divided into two groups: Group LB (Lidocaine-Bupivacaine): A bilateral ESP block will be performed preoperatively (10 ml 1%lidocaine + 10 ml 0.5% bupivacaine). In addition, IV morphine patient-controlled analgesia (PCA) will be applied postoperatively for 24 hours. Group S: A bilateral ESP block will be performed preoperatively (20 ml NS).In addition, IV morphine-PCA will be applied postoperatively for 24 hours.
Investigators
BURHAN DOST
Assistant Professor
Ondokuz Mayıs University
Eligibility Criteria
Inclusion Criteria
- •AmericanSociety of Anesthesiologists (ASA) I-III patients between the ages of 18 and 65 who are scheduled for elective open radical prostatectomy.
- •Exclusion criteria:
- •Patients who do not give informed consent or do not want to participate in the study
- •Ages \<18 or\>65
- •ASA IV patients
- •Obesity (\>100 kg, BMI \>35 kg/m2)
- •Contraindications of regional anesthesia (coagulopathy, thrombocytopenia, or infection at injection site)
- •Serious renal, cardiac, or hepatic disease
- •Hypersensitivity to local anesthetics or a history of allergy
- •History of opioid or steroid use longer than four weeks
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Narcotic consumption in the first 24 hours after surgery
Time Frame: Postoperative day 1
Morphine consumption in the first 24 hours will be measured by IV PCA. Patients will be able to request opioids via a PCA device when their NRS score is above 3.
Secondary Outcomes
- Postoperative nausea and vomiting (PONV)(Postoperative day 1)
- Intraoperative remifentanil consumption(Postoperative day 1)
- Postoperative pain: NRS score(Postoperative day 1)